Indication: Glioblastoma Multiforme (GBM)

Phase II Trial Of AV-GBM-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) As Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma

Newly diagnosed patients

Sub-indication: Glioblastoma Multiforme

Line of Therapy: First line with Temozolomide and RT

Drug Study

Principal Investigator: Renato LaRocca, M.D.
Norton Cancer Institute

Sponsor: AIVITA Biomedical, Inc

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.